Table 3.
Association of LAPTM4B polymorphism with clinicopathologic parameters in prostate cancer patients.
| LAPTM4B |
||||
|---|---|---|---|---|
| Factors | *1/1 | *1/2 | *2/2 | p-value |
| Age at diagnosis (y), n | 0.315 | |||
| ≤ 60 | 55 | 24 | 4 | |
| > 60 | 47 | 31 | 7 | |
| Stage | 0.642 | |||
| pT1 | 7 | 1 | 0 | |
| pT2a | 16 | 10 | 1 | |
| pT2b | 4 | 7 | 1 | |
| pT2c | 42 | 25 | 5 | |
| pT3a | 9 | 3 | 1 | |
| pT3b | 21 | 9 | 2 | |
| PSA at diagnosis (ng/ml), n | 0.826 | |||
| ≤ 4 | 1 | 1 | 0 | |
| 4–10 | 49 | 25 | 6 | |
| >10 | 49 | 28 | 3 | |
| Gleason score, n | 0.843 | |||
| ≤ 6 | 35 | 18 | 4 | |
| 7 | 40 | 26 | 3 | |
| >7 | 24 | 11 | 3 | |
| Perineural invasion, n | 0.886 | |||
| Positive | 59 | 39 | 7 | |
| Negative | 40 | 16 | 3 | |
| Surgical margin, n | 0.813 | |||
| Positive | 39 | 20 | 3 | |
| Negative | 60 | 35 | 7 | |